BR0318201A - regime de dosagem de fármaco antiinflamatório não-esteroidal - Google Patents
regime de dosagem de fármaco antiinflamatório não-esteroidalInfo
- Publication number
- BR0318201A BR0318201A BRPI0318201-0A BR0318201A BR0318201A BR 0318201 A BR0318201 A BR 0318201A BR 0318201 A BR0318201 A BR 0318201A BR 0318201 A BR0318201 A BR 0318201A
- Authority
- BR
- Brazil
- Prior art keywords
- inflammatory drug
- steroidal anti
- drug dosage
- dosage regimen
- steroidal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2003/008846 WO2004093864A1 (en) | 2003-03-21 | 2003-03-21 | Non-steroidal anti-inflammatory drug dosing regimen |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0318201A true BR0318201A (pt) | 2006-03-21 |
Family
ID=33308979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0318201-0A BR0318201A (pt) | 2003-03-21 | 2003-03-21 | regime de dosagem de fármaco antiinflamatório não-esteroidal |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1605929B1 (pt) |
JP (1) | JP2006514982A (pt) |
KR (1) | KR101113005B1 (pt) |
CN (1) | CN1758904A (pt) |
AU (2) | AU2003220467A1 (pt) |
BR (1) | BR0318201A (pt) |
CA (2) | CA2519772C (pt) |
MX (1) | MXPA05010010A (pt) |
NO (1) | NO20054646L (pt) |
WO (1) | WO2004093864A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101458774B1 (ko) | 2007-08-15 | 2014-11-07 | 맥네일-피피씨, 인코포레이티드 | 즉시 방출 및 지속 방출 이부프로펜 투약 계획 |
US9119878B2 (en) | 2010-07-08 | 2015-09-01 | Wellesley Pharmaceuticals, Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
NZ609727A (en) | 2010-11-04 | 2015-07-31 | Aft Pharmaceuticals Ltd | A combination composition comprising ibuprofen and paracetamol |
MY174090A (en) * | 2012-03-19 | 2020-03-09 | Wellesley Pharmaceuticals Llc | Extended-release formulation for reducing the frequency of urination and method of use thereof |
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
CN108348487A (zh) * | 2015-09-01 | 2018-07-31 | 韦尔斯利医药有限公司 | 延迟释放制剂、其制备方法和用途 |
KR20220113567A (ko) | 2021-02-05 | 2022-08-16 | 이광미 | 염증 질환의 개선용 조성물 |
KR20240044914A (ko) | 2022-09-29 | 2024-04-05 | 이광미 | 금속 티오옥토일 히알루로네이트 복합체를 포함하는 염증 질환의 개선용 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2998450A (en) | 1958-05-19 | 1961-08-29 | Warner Lambert Pharmaceutical | Process of preparing nu-acetyl-p-amino phenol |
GB1497044A (en) | 1974-03-07 | 1978-01-05 | Prodotti Antibiotici Spa | Salts of phenyl-alkanoic acids |
US4873231A (en) | 1986-04-08 | 1989-10-10 | Smith Walton J | Decreasing the toxicity of an ibuprofen salt |
CA2061520C (en) | 1991-03-27 | 2003-04-22 | Lawrence J. Daher | Delivery system for enhanced onset and increased potency |
IT1264855B1 (it) | 1993-06-21 | 1996-10-17 | Zambon Spa | Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici |
IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
-
2003
- 2003-03-21 CA CA2519772A patent/CA2519772C/en not_active Expired - Fee Related
- 2003-03-21 EP EP03716776.4A patent/EP1605929B1/en not_active Expired - Lifetime
- 2003-03-21 WO PCT/US2003/008846 patent/WO2004093864A1/en active Application Filing
- 2003-03-21 BR BRPI0318201-0A patent/BR0318201A/pt not_active IP Right Cessation
- 2003-03-21 CA CA2746531A patent/CA2746531C/en not_active Expired - Fee Related
- 2003-03-21 JP JP2004571144A patent/JP2006514982A/ja active Pending
- 2003-03-21 CN CNA038261839A patent/CN1758904A/zh active Pending
- 2003-03-21 AU AU2003220467A patent/AU2003220467A1/en not_active Abandoned
- 2003-03-21 KR KR1020057017690A patent/KR101113005B1/ko active IP Right Grant
- 2003-03-21 MX MXPA05010010A patent/MXPA05010010A/es unknown
-
2005
- 2005-10-10 NO NO20054646A patent/NO20054646L/no not_active Application Discontinuation
-
2010
- 2010-06-30 AU AU2010202751A patent/AU2010202751A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1758904A (zh) | 2006-04-12 |
AU2010202751A1 (en) | 2010-07-22 |
CA2519772C (en) | 2016-05-31 |
KR101113005B1 (ko) | 2012-02-24 |
JP2006514982A (ja) | 2006-05-18 |
KR20060005345A (ko) | 2006-01-17 |
CA2746531C (en) | 2016-06-28 |
MXPA05010010A (es) | 2006-03-10 |
EP1605929B1 (en) | 2014-04-23 |
NO20054646L (no) | 2005-10-10 |
CA2746531A1 (en) | 2004-11-04 |
WO2004093864A1 (en) | 2004-11-04 |
AU2003220467A1 (en) | 2004-11-19 |
CA2519772A1 (en) | 2004-11-04 |
EP1605929A1 (en) | 2005-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE247477T1 (de) | Inhalierbare medizinische aerosolzubereitung zur behandlung oder verbeugung von schmerz | |
MX2009013574A (es) | Formas de dosificacion solidas o semisolidas de liberacion modificada. | |
CY1110842T1 (el) | Φαρμακευτικες συνθεσεις για τη συντονισμενη διανομη των μσαφ | |
CY1117656T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
MX2009005339A (es) | Suspensiones analgesicas de liberacion modificada. | |
BR0308250A (pt) | Métodos de indução de diferenciação terminal | |
ATE543491T1 (de) | Kombinationspräparat enthaltend ibuprofen und paracetamol | |
ATE476972T1 (de) | Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris | |
DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
HUP0203325A2 (hu) | Biciklusos aminosavak, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20062450L (no) | Analgesiske suspensjoner med kontrollert frigivelse | |
NO20054646L (no) | Doseringskur for ikke-steroidalt anti-inflammatorisk legemiddel | |
NO20062442L (no) | Analgesiske suspensjoner md kontrollert frigivelse | |
DE602007012904D1 (de) | Neue 2',3'-methylidenacetyladenosine prodrugs zur | |
BRPI0503821A (pt) | uso de antitripsina alfa-1 para a preparação de medicamentos para o tratamento de fibromialgia e método de tratamento | |
EA200401454A1 (ru) | Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний | |
PE20040176A1 (es) | Ambroxol para el tratamiento de dolores cronicos | |
PT1583525E (pt) | Utilização de uma combinação de substâncias da síntese de porfirina, salicilatos e anti-oxidantes na fototerapia de doenças da pele e/ou das articulações | |
WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations | |
WO2008000744A3 (en) | 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor | |
Kuzmin | Postoperative analgesia with nephopam hydrochloride in plastic surgery | |
BR0312333A (pt) | Terapia de combinação e agente para sua execução | |
WO2004110378A3 (en) | Treatment alzheimer's disease with r(-) 2-arylproponic acid nsaid alone or in combination with selective cox-2 inhibitor | |
WO2003066806A3 (en) | Therapeutic use of aziridino compounds | |
HUP0401294A2 (hu) | Acetil-L-karnitin alkalmazása fájdalom megelőző terápiájára szolgáló gyógyászati készítmény előállítására |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA.INT.CI. A61K 31/192, A61K 31/195, A61K 31/38, A61K 31/40, A61P 29/00 Ipc: A61K 31/192 (2011.01), A61K 31/195 (2011.01), A61K |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI |
|
B12B | Appeal: appeal against refusal | ||
B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 18A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |